<DOC>
	<DOCNO>NCT02581059</DOCNO>
	<brief_summary>This randomize , multi-center phase II study ginseng colorectal cancer patient treat regorafenib determine ginseng reduce fatigue patient population improve adherence regorafenib . Ninety ( 90 ) subject enrol randomize use 2:1 allocation , 60 subject enrol regorafenib + ginseng group 30 enrol regorafenib + ginseng group .</brief_summary>
	<brief_title>Efficacy Ginseng Patients Regorafenib</brief_title>
	<detailed_description>OUTLINE : This multi-center study . INVESTIGATIONAL TREATMENT : Regorafenib administer 160 mg orally daily first 21 day 28-day cycle . Subjects randomize receive ginseng take 1,000 mg orally twice daily every day 4 week ( 2 cycle ) . Subjects randomize NOT receive ginseng give ginseng . Subjects instruct take regorafenib low-fat meal . Subjects undergo fatigue assessment , use MFSI-SF instrument PROMIS . Subjects pill count C2D1 end treatment visit . Subjects re-staging scan ( CT chest/abdomen/pelvis ) end Cycle 2/ week 8 ( ±5 ) . Adequate bone marrow , liver renal function assess follow laboratory value obtain within 7 day prior registration protocol therapy : Hematopoietic : - Absolute neutrophil count ( ANC ) count &gt; 1,500/mm^3 - Hemoglobin ( Hgb ) &gt; 9g/dL - Platelet count &gt; 100,000/mm^3 Renal : - Serum creatinine ≤ 1.5 × upper limit normal ( ULN ) Hepatic : - Total bilirubin ≤ 1.5 × upper limit normal ( ULN ) . - Alanine aminotransferase ( ALT ) aspartate amino-transferase ( AST ) ≤ 2.5 x ULN ( ≤ 5 × ULN subject liver involvement cancer ) - Alkaline phosphatase ( ALP ) limit ≤ 2.5 × ULN ( ≤ 5 × ULN subject liver involvement cancer ) Coagulation : - International normalized ratio ( INR ) /Partial thromboplastin time ( PTT ) ≤ 1.5 × ULN . NOTE : Subjects prophylactically treat agent warfarin heparin allow participate prior evidence underlie abnormality coagulation parameter exist . Close monitoring least weekly evaluation perform INR/PTT stable , base measurement pre-dose define local standard care . Warfarin exceed 1 mg .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Subjects must able understand willing sign write informed consent Health Insurance Portability Accountability Act 1996 ( HIPAA ) authorization release personal health information . A sign informed consent form ( ICF ) must appropriately obtain prior conduct trialspecific procedure . NOTE : HIPAA authorization may include informed consent obtain separately . Age ≥ 18 year time consent . Life expectancy least 12 week ( 3 month ) determine treat physician . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 within 28 day prior registration . Histological pathologically confirm stage IV adenocarcinoma colon . Women childbearing potential must negative serum pregnancy test perform within 7 day prior start study drug . Postmenopausal woman ( defined menses least 1 year ) surgically sterilize woman require undergo pregnancy test . Subjects ( men woman ) childbearing potential must agree use adequate contraception begin sign ICF least 2 month last dose study drug . The definition adequate contraception base judgment treat physician designate associate . NOTE : Examples adequate contraception may include limited combination two following : use oral , injected implant hormonal method contraception ; placement intrauterine device ( IUD ) intrauterine system ( IUS ) ; barrier method contraception ( condom occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/ film/cream/vaginal suppository ) ; total abstinence ; male/female sterilization All subject must radiographically assessable disease per RECIST v1.1 obtain image within 28 day prior registration . Must able swallow retain oral medication . Subject must deem suitable candidate regorafenib per treat physician . Subject receive agent fatigue include steroid , megace opioids . NOTE : Subjects contrastinduced allergy allow receive steroid scan . Radiotherapy within 2 week prior study registration . Subjects must recover therapyrelated toxicity . Prior treatment regorafenib . Previous assignment treatment study . Subjects permanently withdraw study participation allow reenter study . Congestive heart failure &gt; New York Heart Association ( NYHA ) class 2 : unstable angina ( angina symptom rest ) , newonset angina ( begin within last 3 month ) , myocardial infarction le 6 month study registration ; cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) ; uncontrolled hypertension ( systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg despite optimal medical management ) . Evidence history bleed diathesis coagulopathy . Any hemorrhage bleeding event ≥ NCI CTCAE Grade 3 within 4 week prior study registration . Subjects thrombotic , embolic , venous , arterial event , cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism within 6 month study registration . Previous concurrent cancer distinct primary site histology colorectal cancer within 3 year prior randomization EXCEPT curatively treat cervical cancer situ , nonmelanoma skin cancer superficial bladder tumor [ Ta ( Noninvasive tumor ) , Tis ( Carcinoma situ ) T1 ( Tumor invade lamina propria ) ] . Subjects pheochromocytoma . Known history human immunodeficiency virus ( HIV ) infection current chronic active hepatitis B C infection require treatment antiviral therapy . Ongoing infection &gt; Grade 2 NCICTCAE v4.0 . Metastatic brain meningeal tumor ( symptomatic asymptomatic ) . Major surgical procedure significant traumatic injury , define site investigator , within 28 day study registration . Renal failure require hemo peritoneal dialysis Dehydration Grade &gt; 2 NCI CTCAE v4 within 7 day prior registration . Subjects seizure disorder currently require medication . Persistent proteinuria ≥ Grade 3 NCI CTCAE v4.0 define &gt; 3.5 g/24 hour , measure urine protein : creatinine ratio random urine sample . Interstitial lung disease ongoing sign symptom time study registration . Pleural effusion ascites cause respiratory compromise ( ≥ NCI CTCAE version 4.0 Grade 2 dyspnea ) . History organ allograft ( include corneal transplant ) . Known suspected allergy hypersensitivity study drug , study drug class , excipients formulation give course trial . Any malabsorption condition , opinion treat physician , affect absorption agent use study . Women pregnant breastfeeding . Any condition , , site investigator 's opinion , make subject unsuitable trial participation . Substance abuse , medical , psychological , social condition may interfere subject 's participation study evaluation study result . Treatment investigational agent within 28 day prior registration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Regorafenib</keyword>
	<keyword>American Ginseng</keyword>
	<keyword>Fatigue</keyword>
</DOC>